{"success":true,"data":{"pressRelease":{"id":"61674","rtpr_id":"nGNX78ZnY0","ticker":"ZTS","exchange":"NYSE","all_tickers":["ZTS"],"title":"Bronstein, Gewirtz & Grossman LLC Urges Zoetis Inc. Investors to Act: Class Action Filed Alleging Investor Harm","author":"Globe Newswire","published_at":"2026-06-11T16:00:00.384Z","article_body":"NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman,\nLLC, a nationally recognized investor-rights law firm, announces that a class\naction lawsuit has been filed against Zoetis Inc. (NYSE: ZTS) and certain of\nits officers.\n\nThis lawsuit seeks to recover damages against Defendants for alleged\nviolations of the federal securities laws on behalf of all persons and\nentities that purchased or otherwise acquired Zoetis securities between\nJanuary 14, 2025 and May 6, 2026, both dates inclusive (the “Class\nPeriod”). Such investors are encouraged to join this case by visiting the\nfirm’s site: bgandg.com/ZTS.\n(https://www.globenewswire.com/Tracker?data=fIrH83vbJxgzbVUeewfVcev_cD0ZRnxhRQpKFsbODRfA4YV6W3wGoDBDJX8HpiOhIYB8CDs4rHienlPiK9sIR28P0uITghfqDp_Ot09OOuxKvTQ0FJoL0zPo-JweiWgfKcsxdanRDNFL7DPuywMr4GQoMO1JuUwScUk7SAr74uc=)\n\nZoetis Case Details\n\nThe Complaint alleges that, throughout the Class Period, Defendants made\nmaterially false and misleading statements concerning the growth, competitive\npositioning, market share, and veterinarian adoption of key products within\nthe Companion Animal segment while failing to disclose that:\n\n(1) veterinarian prescription growth and adoption of Zoetis’ Librela, a\ncanine pain treatment, were sharply weakening as clinicians became more\ncautious following FDA safety warnings concerning serious neurological\ncomplications in dogs; \n(2)  Zoetis’ Simparica Trio was losing significant market share to a\nlower-priced competing canine parasiticide with broader indicated use in a\nslowing overall market; and \n(3)  Zoetis’ dermatology products, Apoquel and Cytopoint, were losing\nsubstantial market share to a newly launched competing canine treatment.\n\nWhat's Next for Zoetis Investors?\n\nA class action lawsuit has already been filed. If you wish to review a copy of\nthe Complaint, you can visit the firm’s site: bgandg.com/ZTS.\n(https://www.globenewswire.com/Tracker?data=fIrH83vbJxgzbVUeewfVcbseyd_QqHK4A80_-Go-xNX6kNACe08jhRSrae5_oa4kRE7r9H5Q7wFlaHY7OMfGtwWMp2J-J1i3cnNnBUUwAqS9mAy94VGjQBC6Z3HjR0i4ycZIkGXn1yVejFwP1MXCLTRC7n8Nwy0LaVKKDuX5quI=)\nor you may contact Peretz Bronstein, Esq. or his Client Relations Manager,\nNathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you\nsuffered a loss in Zoetis you have until July 27, 2026, to request that the\nCourt appoint you as lead plaintiff. Your ability to share in any recovery\ndoesn't require that you serve as lead plaintiff.\n\nNo Cost to Zoetis Investors\n\nWe, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on\na contingency fee basis. That means we will ask the court to reimburse us for\nout-of-pocket expenses and attorneys’ fees, usually a percentage of the\ntotal recovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Zoetis Securities Class Action?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide. More at www.bgandg.com\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://www.globenewswire.com/Tracker?data=CPKKEYSIxWHyuThMsLliXLNGZF-gdJ718WwDHBTaIRzNgxPRmyb0xkzCm3yjNNa1t8Cp7L17nA3JpK2MVfF7EvATs4OaSGIXFQbvp386vDyWTvyGg8_qG-_8s6mVWw3r-dAdKpgyx-B-sciaLmYS6g==),\nFounding Partner of Bronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://www.globenewswire.com/Tracker?data=1EOq4QKfiQpOzsjcgwQkuam-47MtD5fpyuCHf_OKoi6WZ6LuN22JdGkSs1iq1Tq6ARYBkQBZ3POaMYpGu7lDiStcHnYiiow8g98kmfcAiE9ry4Bmf_7hb61bRg4a-TvEg-X5BVpz7QDcPde0SOWm3w==),\nX\n(https://www.globenewswire.com/Tracker?data=Y4MHr-jYyET3h3SEiQbsDoyUe_GZ0aP1Hl0XaxgQzZhKU2y5V40RPss4N6qTdPmOUwo_i11LStcH2ZSHNlZLhg==),\nFacebook\n(https://www.globenewswire.com/Tracker?data=7bYQ4-993X9afThHxmhFe0Vb5_tpBP2zxA9lHA-h_jJ74qhL70VH6gGz_iqk8Rx4hFofBu6TLq8Jz1yDd2PX9Kn_qsWMJ9CwtaeBkmN0Bkw=),\nor Instagram\n(https://www.globenewswire.com/Tracker?data=bkCsX0uMFdOxS79lzylYEOSGcYbfvrQsTztwpE8o0lEAuRK58lKmqkw894JPAlPOjd8wu15I6DT1xPb_NtNEPrKO8NjnthE6rMRZqxYys7g=).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 | info@bgandg.com\n\nAttorney advertising.\nPrior results do not guarantee similar outcomes.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1a031130-a9cc-48ff-b281-d1e47c9a91a5)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX78ZnY0","title":"Bronstein, Gewirtz & Grossman LLC Urges Zoetis Inc. Investors to Act: Class Action Filed Alleging Investor Harm","author":"Globe Newswire","ticker":"ZTS","created":"2026-06-11T16:00:00.384Z","tickers":["ZTS"],"exchange":"NYSE","article_body":"NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman,\nLLC, a nationally recognized investor-rights law firm, announces that a class\naction lawsuit has been filed against Zoetis Inc. (NYSE: ZTS) and certain of\nits officers.\n\nThis lawsuit seeks to recover damages against Defendants for alleged\nviolations of the federal securities laws on behalf of all persons and\nentities that purchased or otherwise acquired Zoetis securities between\nJanuary 14, 2025 and May 6, 2026, both dates inclusive (the “Class\nPeriod”). Such investors are encouraged to join this case by visiting the\nfirm’s site: bgandg.com/ZTS.\n(https://www.globenewswire.com/Tracker?data=fIrH83vbJxgzbVUeewfVcev_cD0ZRnxhRQpKFsbODRfA4YV6W3wGoDBDJX8HpiOhIYB8CDs4rHienlPiK9sIR28P0uITghfqDp_Ot09OOuxKvTQ0FJoL0zPo-JweiWgfKcsxdanRDNFL7DPuywMr4GQoMO1JuUwScUk7SAr74uc=)\n\nZoetis Case Details\n\nThe Complaint alleges that, throughout the Class Period, Defendants made\nmaterially false and misleading statements concerning the growth, competitive\npositioning, market share, and veterinarian adoption of key products within\nthe Companion Animal segment while failing to disclose that:\n\n(1) veterinarian prescription growth and adoption of Zoetis’ Librela, a\ncanine pain treatment, were sharply weakening as clinicians became more\ncautious following FDA safety warnings concerning serious neurological\ncomplications in dogs; \n(2)  Zoetis’ Simparica Trio was losing significant market share to a\nlower-priced competing canine parasiticide with broader indicated use in a\nslowing overall market; and \n(3)  Zoetis’ dermatology products, Apoquel and Cytopoint, were losing\nsubstantial market share to a newly launched competing canine treatment.\n\nWhat's Next for Zoetis Investors?\n\nA class action lawsuit has already been filed. If you wish to review a copy of\nthe Complaint, you can visit the firm’s site: bgandg.com/ZTS.\n(https://www.globenewswire.com/Tracker?data=fIrH83vbJxgzbVUeewfVcbseyd_QqHK4A80_-Go-xNX6kNACe08jhRSrae5_oa4kRE7r9H5Q7wFlaHY7OMfGtwWMp2J-J1i3cnNnBUUwAqS9mAy94VGjQBC6Z3HjR0i4ycZIkGXn1yVejFwP1MXCLTRC7n8Nwy0LaVKKDuX5quI=)\nor you may contact Peretz Bronstein, Esq. or his Client Relations Manager,\nNathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you\nsuffered a loss in Zoetis you have until July 27, 2026, to request that the\nCourt appoint you as lead plaintiff. Your ability to share in any recovery\ndoesn't require that you serve as lead plaintiff.\n\nNo Cost to Zoetis Investors\n\nWe, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on\na contingency fee basis. That means we will ask the court to reimburse us for\nout-of-pocket expenses and attorneys’ fees, usually a percentage of the\ntotal recovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Zoetis Securities Class Action?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide. More at www.bgandg.com\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://www.globenewswire.com/Tracker?data=CPKKEYSIxWHyuThMsLliXLNGZF-gdJ718WwDHBTaIRzNgxPRmyb0xkzCm3yjNNa1t8Cp7L17nA3JpK2MVfF7EvATs4OaSGIXFQbvp386vDyWTvyGg8_qG-_8s6mVWw3r-dAdKpgyx-B-sciaLmYS6g==),\nFounding Partner of Bronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://www.globenewswire.com/Tracker?data=1EOq4QKfiQpOzsjcgwQkuam-47MtD5fpyuCHf_OKoi6WZ6LuN22JdGkSs1iq1Tq6ARYBkQBZ3POaMYpGu7lDiStcHnYiiow8g98kmfcAiE9ry4Bmf_7hb61bRg4a-TvEg-X5BVpz7QDcPde0SOWm3w==),\nX\n(https://www.globenewswire.com/Tracker?data=Y4MHr-jYyET3h3SEiQbsDoyUe_GZ0aP1Hl0XaxgQzZhKU2y5V40RPss4N6qTdPmOUwo_i11LStcH2ZSHNlZLhg==),\nFacebook\n(https://www.globenewswire.com/Tracker?data=7bYQ4-993X9afThHxmhFe0Vb5_tpBP2zxA9lHA-h_jJ74qhL70VH6gGz_iqk8Rx4hFofBu6TLq8Jz1yDd2PX9Kn_qsWMJ9CwtaeBkmN0Bkw=),\nor Instagram\n(https://www.globenewswire.com/Tracker?data=bkCsX0uMFdOxS79lzylYEOSGcYbfvrQsTztwpE8o0lEAuRK58lKmqkw894JPAlPOjd8wu15I6DT1xPb_NtNEPrKO8NjnthE6rMRZqxYys7g=).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 | info@bgandg.com\n\nAttorney advertising.\nPrior results do not guarantee similar outcomes.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1a031130-a9cc-48ff-b281-d1e47c9a91a5)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-11T16:00:00.458816526Z","server_sent_at_ms":1781193600458},"received_at":"2026-06-11T16:00:00.609Z","source_url":null},"analysis":{"id":"51113","press_release_id":"61674","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Bronstein, Gewirtz & Grossman LLC issued a press release announcing a class action lawsuit filed against Zoetis Inc. and certain officers.\n\nThe firm encourages investors who purchased ZTS securities between January 14, 2025, and May 6, 2026, to join the case and contact the firm.\n\nThis is a routine plaintiff-firm solicitation for lead plaintiff designation, not an issuer disclosure or court ruling.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace","namedEntities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner, Bronstein, Gewirtz & Grossman LLC"},{"name":"Nathan Miller","role":"Client Relations Manager, Bronstein, Gewirtz & Grossman LLC"}],"products":["Librela","Simparica Trio","Apoquel","Cytopoint"],"companies":[{"name":"Bronstein, Gewirtz & Grossman LLC","relationship":"plaintiff law firm"},{"name":"Zoetis Inc.","ticker":"ZTS"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Bronstein, Gewirtz & Grossman LLC. No new disclosure from the issuer; no certified class, no settlement. Boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"ZTS"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"large-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Bronstein, Gewirtz & Grossman LLC issued a press release announcing a class action lawsuit filed against Zoetis Inc. and certain officers.\n\nThe firm encourages investors who purchased ZTS securities between January 14, 2025, and May 6, 2026, to join the case and contact the firm.\n\nThis is a routine plaintiff-firm solicitation for lead plaintiff designation, not an issuer disclosure or court ruling.","key_figures":{},"named_entities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner, Bronstein, Gewirtz & Grossman LLC"},{"name":"Nathan Miller","role":"Client Relations Manager, Bronstein, Gewirtz & Grossman LLC"}],"products":["Librela","Simparica Trio","Apoquel","Cytopoint"],"companies":[{"name":"Bronstein, Gewirtz & Grossman LLC","relationship":"plaintiff law firm"},{"name":"Zoetis Inc.","ticker":"ZTS"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-11T16:07:55.336Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"large-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":437331,"modelName":"george-droid-qwen-72b"}}